Table 2. Histopathologic and immunohistochemical features of the xenografts and their respective donor tumors.
| Xenograft no.-subline no. | Diagnosis | ARa | PSA | Chromogranin Ab | Synaptophysinb | UBE2Ca | Cyclin D1a | RBa | KI67a |
|---|---|---|---|---|---|---|---|---|---|
| 79 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa | 95 | 90 | neg | neg | 1 | 10 | 50 | 10 |
| MDA PCa 79 | AdCa | 90 | 10c | neg | neg | 10 | <1 | 100 | 15 |
|
| |||||||||
| 117 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa with NE diff | 70 | 80 | pos | pos | 15 | 30 | 90 | 10 |
| MDA PCa 117-9 | AdCa with NE diff | 95 | 10 | pos | pos | 20 | 50 | 100 | 10 |
|
| |||||||||
| 130 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa | 95 | 80 | neg | neg | 20 | 70 | 100 | 10 |
| MDA PCa 130 | AdCa | 80 | 40 | neg | neg | 30 | 70 | 95 | 10 |
|
| |||||||||
| 144 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa | 90 | 40 | neg | neg | 5 | 20 | 5 | 30 |
| SCPC | <1 | <1 | pos | pos | 60 | 0 | 0 | 95 | |
| LCNEC | <1 | 5 | pos | pos | 40 | 0 | N/A | 95 | |
| MDA PCa 144-13 | SCPC | 0 | 0 | pos | pos | 60 | 0 | 0 | 85 |
| MDA PCa 144-4 | LCNEC | 0 | 0 | pos | pos | 40 | 0 | 0 | 95 |
|
| |||||||||
| 146 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa | 90 | 20 | neg | neg | 10 | 0 | 0 | 20 |
| SCPC | 0 | 0 | pos | pos | 40 | 0 | 0 | 95 | |
| MDA PCa 146-10 | SCPC | 0 | 0 | pos | pos | 50 | 0 | 0 | 60 |
| MDA PCa 146-17 | SCPC | 0 | 0 | pos | pos | 30 | 0 | 0 | 40 |
| MDA PCa 146-20 | SCPC | 0 | 0 | pos | pos | 40 | 0 | 0 | 60 |
|
| |||||||||
| 155 | |||||||||
|
| |||||||||
| Donor Tumor | SCPC | 0 | 0 | pos | pos | 50 | 5 | 2 | 50 |
| MDA PCa 155-2 | SCPC | 0 | 0 | pos | pos | 50 | 0 | 0 | 30 |
| MDA PCa 155-9 | SCPC | 0 | 0 | pos | pos | 60 | 0 | 0 | 40 |
| MDA PCa 155-12 | SCPC | 0 | 0 | pos | pos | 40 | 0 | 0 | 40 |
| MDA PCa 155-16 | SCPC | 0 | 0 | pos | pos | 70 | 0 | 0 | 50 |
|
| |||||||||
| 170 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa | 95 | 20 | neg | neg | 10 | 70 | 100 | 25 |
| MDA PCa 170-1 | AdCa | 100 | 60 | neg | neg | 25 | 80 | 100 | 30 |
| MDA PCa 170-4 | AdCa | 95 | 15 | neg | neg | 15 | 75 | 100 | 55 |
|
| |||||||||
| 180 | |||||||||
|
| |||||||||
| Donor Tumor | AdCa with NE diff | 90 | 5 | neg | pos | 20 | 20 | 100 | 30 |
| MDA PCa 180-11 | AdCa with NE diff | 95 | 0 | neg | pos | 25 | 30 | 100 | 70 |
| MDA PCa 180-14 | AdCa with NE diff | 100 | 0 | neg | pos | 20 | 25 | 100 | 50 |
| MDA PCa 180-18 | AdCa with NE diff | 100 | 5 | neg | pos | 15 | 50 | 100 | 60 |
| MDA PCa 180-21 | AdCa with NE diff | 100 | 5 | neg | pos | 35 | 50 | 100 | 80 |
| MDA PCa 180-30 | AdCa with NE diff | 95 | 5 | neg | pos | 20 | 50 | 100 | 50 |
a
Percentage of positive cells.
b
neg:≤5% positive cells, pos:>5% positive cells
c
Note that some discrepancies between donor and xenograft immunohistochemical profiles exist, likely as a result of clonal selection in xenograft establishment. Nonetheless, all xenografts were shown to mirror the section of the donor tumor from which they were obtained.
Abbreviations: DT, donor tumor; AdCa, adenocarcinoma; NE, neuroendocrine; neg, negative; pos, positive; N/A, not available